From their meeting in February, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights. During the meeting the CHMP announced the recommendations of eight medicines for approval, including two orphan medicines. For three out of the eight new medicines, the CHMP recommended a conditional marketing authorisation. Read more “Highlights from the February CHMP meeting”
Category: Industry news
European Union advances towards adopting SPC waiver proposal
The European Union (EU) is adopting new rules which aim to increase the competitiveness of EU producers of generic medicines and biosimilar products. The EU’s proposal to allow manufacturing waivers to supplementary protection certificates (SPC) advances after EU ambassadors approved a compromise that was reached on 14th February with the European Parliament during a meeting of the Committee of the Permanent Representatives. Read more “European Union advances towards adopting SPC waiver proposal”
No-deal Brexit guidance for manufacturers of biological medicines
If the United Kingdom (UK) leaves the European Union (EU) with no-deal, the National Institute for Biological Standards and Control (NIBSC) will become a stand-alone National Control Laboratory. Read more “No-deal Brexit guidance for manufacturers of biological medicines”
EMA opens consultation on the role of ‘big data’ for evaluation and supervision of medicines in the EU
As part of a report of the Heads of Medicines Agencies (HMA) – European Medicines Agency (EMA) Joint Big Data task force, recommendations and associated actions have been outlined for understanding the acceptability of evidence which is derived from ‘big data’ in support of the evaluation and supervision of medicines by regulators. Read more “EMA opens consultation on the role of ‘big data’ for evaluation and supervision of medicines in the EU”
Partial US Government shutdown is straining the FDA
A partial United States (US) Government shutdown has hindered the Food and Drug Administration’s (FDA’s) ability to accept and review regulatory submissions. A notice from the FDA on Government funding lapses, which started in December 2018, states that currently the FDA has no legal authority to collect user fees assessed for their 2019 fiscal year, which prevents the FDA from accepting new regulatory submissions such as 510(k)s and Premarket Applications (PMA) that require fees until Congress and the White House restore full funding. If you are planning to submit applications for US market authorisation in early 2019, you should factor these operational delays at FDA into your commercialisation plans. Read more “Partial US Government shutdown is straining the FDA”
Highlights from the December CHMP meeting
From their meeting in December, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has published the highlights. During the meeting, the CHMP announced the recommendations of seven medicines for approval, including two orphan medicines. Read more “Highlights from the December CHMP meeting”
FDA introduces expectations for biosimilars, soon to be biologics
The Food and Drug Administration (FDA) have released two new draft question and answers (Q&A) documents on biosimilar development, and the deemed to be a license provision of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), and two final guidance documents covering the same topics, plus one proposed rule which amends the definition of a biological product. Read more “FDA introduces expectations for biosimilars, soon to be biologics”
France to create clinical trial fast track for cell and gene therapies
France’s Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) are to create a fast track for applications to run clinical trials of cell and gene therapies. The proposed regulatory process will reduce the time it takes sponsors to receive authorisation to start clinical trials to 110 days. Read more “France to create clinical trial fast track for cell and gene therapies”
FDA framework to advance use of real-world evidence to support development of drugs and biologics
The Food and Drug Administration (FDA) have released a new framework which discusses how the agency will use real world evidence (RWE) and real-world data (RWD) to assist companies win new indications for approved drugs and biologics, expand labels or satisfy post-approval study requirements. Read more “FDA framework to advance use of real-world evidence to support development of drugs and biologics”
EMA revises guideline on environmental risk assessment of human medicines
The updated European Medicines Agency (EMA) draft guideline on environmental risk assessment (ERA) now contains a decision tree which clarifies when ERA studies are required, and provides greater detail on technical guidance to help increase the consistency of the assessments. Performing an ERA is mandatory for any pharmaceutical company submitting a marketing authorisation application for a medicine. Read more “EMA revises guideline on environmental risk assessment of human medicines”